Gelesis Investor Relations Material
Latest events
Q4 2022
Gelesis
Investor Presentation
7 Sep, 2023
Q2 2023
14 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Gelesis Holdings Inc
Access all reports
Gelesis Holdings Inc. is a biotechnology company focused on developing products for weight management and metabolic health. The company creates therapeutics designed to treat obesity and other related conditions using hydrogel technology. Gelesis’ products are intended to aid in weight loss by creating a sensation of fullness, and they are based on its proprietary biomaterials platform. The company’s offerings target individuals seeking weight management solutions and those at risk of obesity-related health issues. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NYSE.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
GLS
Country
🇺🇸 United States